Supriya Lifescience Limited (NSE: SUPRIYA, BSE: 543434) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹7,131 Cr, it ranks #707 by market cap among the 6,137 Indian listed companies on FinBizNet, and #22 of 86 in Medicinal Chemicals and Botanical Products. At ₹818.55 (as of 25 Oct 2026), the share price is 24.6% below its 52-week high of ₹1,085.00 and 50.1% above its 52-week low of ₹545.50. The share price is up 13.6% over one year and down 2.6% over three months.
| Current Price | ₹818.55 |
|---|---|
| Market Cap | ₹7,131 Cr |
| NSE Symbol | SUPRIYA |
| BSE Code | 543434 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 33.7 |
| Return on Equity | 19.06% |
| Return on Assets | 13.46% |
| 52-Week Range | ₹545.50 – ₹1,085.00 |
| 1-Year Price Change | +13.6% |
| 3-Month Price Change | -2.6% |
| Beta (1Y) | 0.54 |
| Dividend Yield | 0.11% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.supriyalifescience.com |
| Revenue | ₹190 Cr |
|---|---|
| Net Profit | ₹24 Cr |
| Net Margin | 12.7% |
| EPS (Basic) | ₹2.99 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.
1. Specialty Chemicals-This segment engages in the research and development, manufacture, and sale of active pharmaceutical ingredients.
1. Specialty Chemicals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Supriya Lifescience Limited | ₹7,131 Cr | 33.7 | 19.06% | ₹190 Cr | +13.6% |
Listed by market capitalisation. Ratios are shown for context only.
Supriya Lifescience Limited is trading at ₹818.55, with a market capitalisation of ₹7,131 Cr.
Supriya Lifescience Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Supriya Lifescience Limited has a P/E of 33.7 and a return on equity of 19.06%.
Supriya Lifescience Limited is listed on the NSE under the symbol SUPRIYA and on the BSE under the scrip code 543434.
Supriya Lifescience Limited's share price is up 13.6% over one year and down 2.6% over three months. Its 52-week range is ₹545.50 to ₹1,085.00.
In Q1 FY27, Supriya Lifescience Limited reported revenue of ₹190 Cr and net profit of ₹24 Cr, with basic EPS of ₹2.99 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.